Antibody + Drug + Third Party, Antibody + siRNAASO + Third Party
Single Use Technologies (SUT) in Pharmaceutical Manufacturing
The Increasing Importance of Manufacturability in API Development
Redefining RNA Manufacturing Through Innovation in Biocatalysis
Navigating the U.S. CDMO Industry
EDITORIAL SECTION
-
STRATEGY
Strategic Positioning for M&A
The biotechnology sector is characterised by a constant influx of small highly specialised companies
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solutions help reduce contamination risk and lower manual handling
-
CLINICAL TRIALS
Virtual Clinical Trials
Virtual digital and decentralized are all descriptions of the novel ways that using technology changes
-
Bio Pharma
Biosimilars and Biobetters
Biosimilars are biologic medical products that are essentially identical to an original product manufactured
-
MANUFACTURING
Transformative Convergence of AI in Pharmaceutical Manufacturing
The pharmaceutical manufacturing industry is on the cusp of a revolutionary transformation driven by
-
Information Technology
Transformative Impact of Artificial Intelligence on Clinical Trials
Artificial Intelligence AI has rapidly evolved from a futuristic concept to a transformative tool across various industries
-
EXPERT Talk
The Quiet Disciplines of High-Performance Labs: Talent, Modalities, and the Data-Native Future
In smallmolecule work a competent team can be built by hiring for HPLC method validation and impurity characterisation The playbook is established the...
Advisory Board
.webp "Juris Hmelnickis")
.webp "Eiman Shafa")
KNOWLEDGE BANK
-
Articles
Forgotten Biology: The Missing Link Behind Trial Outcomes
Clinical trials are often described as the science of uncertainty and that uncertainty is expected It is how evidence is built However not all uncertainty is scientific In many cases it arises when the biological context of an intervention is not carried through into the study population
-
Techno Trends
FORE Biotherapeutics Receives FDA Breakthrough Therapy Designation for Plixorafenib in Brain Cancer
FORE Biotherapeutics has received Breakthrough Therapy Designation from the US Food and Drug Administration FDA for its investigational drug plixorafenib developed for the treatment of adult patients with BRAF VEmutated highgrade glioma a severe form of brain cancer
-
Projects
Cambrex Announces $150 Million Expansion across U.S. and European Facilities
Cambrex has revealed significant progress on its expansion initiatives across the United States and Europe These projects are designed to boost capacity for manufacturing complex drugs
-
Research Insights
Interpretable multivariate survival models: Improving predictions for conversion from mild cognitive impairment to Alzheimer’s disease via data fusion and machine learning
Accurately predicting which individuals with mild cognitive impairment MCI will progress to Alzheimers disease AD can improve patient care This study examines the role of quantitative MRI qMRI cognitive evaluations
-
White Papers
Accelerating In-Vitro Antibody Discovery with Artificial Intelligence
Antibodies have transformed modern medicine reshaping treatment paradigms across autoimmune disorders oncology and infectious diseases As one of the most versatile and successful therapeutic modalities
TOP ARTICLES
-
1
Innovative Biosafety Testing: Driving Manufacturing Excellence
Kate Williamson
Innovative Biosafety Testing: Driving Manufacturing Excellence explores the pivotal role of advanced biosafety testing in ensuring product safety, regulatory compliance, and market competitiveness in...
-
2
Anti-CRISPR Proteins: A Biological Safety Switch for Precise Gene Editing
Fatemeh Akhoondi
CRISPR has become a powerful tool for gene editing, yet achieving safe and precise control remains challenging. Anti-CRISPR (Acr) proteins provide a natural way to slow or stop Cas enzymes when needed...
-
3
ABM Pharma Tactics US: Unlocking B2B Lead Gen Success
Kate Williamson
The Account-based marketing (ABM) pharma strategies are reshaping the US B2B pharma marketing by focusing the high value accounts rather than the lead volume. Pharmaceutical account-based marketing en...
-
4
Enhancing Patient Care with Digital Tools in the Pharmaceutical Sector
Kate Williamson
Digital tools are proliferating productive millennium patients care in the global pharmaceutical Industry by widening access, liabilities, and tailored therapy. Using such technologies as mobile appli...
-
5
Bridging the Gap: Advancing In Vitro to In Vivo Gene Therapies
Kate Williamson
Bridging the Gap: Advancing In Vitro to In Vivo Gene Therapies explores the challenges and innovations in transitioning gene therapies from laboratory success to clinical application. Highlighting adv...
press releasesRead more...
Bayer to Acquire Perfuse Therapeutics to Complement Ophthalmology Pipeline
Bayer and Perfuse Therapeutics Inc today announced an agreement under which Bayer will fully acquire Perfuse Therapeutics a biopharmaceutical company pioneering transformational research
CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis
Johnson Johnson NYSE JNJ today announced findings from the first network metaanalysis NMA comparing CAPLYTA lumateperone to FDAapproved atypical antipsychotics for addon treatment
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome
Atossa Therapeutics Inc a clinicalstage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need today announced that the US Food and Drug Administration FDA
Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors
Immunome Inc Nasdaq IMNM a biotechnology company committed to developing firstinclass and bestinclass targeted cancer therapies today announced the submission of a New Drug Application NDA to the US Food and Drug Administration
Events Read more...
05 - 06
May 2026GENAP Summit 2026
Vienna, Austria
06 - 07
May 20262nd Edition MaxPotent Pharma Summit 2026
Milan, Italy
06 - 07
May 202641th pharmacovigilance USA 2026
Boston, USA
07 - 08
May 202621st PPM for Pharma & Biotech
New Jersey, USA
10 - 14
May 2026Respiratory Drug Delivery 2026
The Westin Kierland Phoenix, Arizona, USA
20 - 21
May 2026Pharmacovigilance Europe 2026
London, UK
20 - 22
May 2026PHARMA EURASIA 2026
Pharma & Med Tech Park, Tashkent, Uzbekistan
20 - 21
May 2026Pharma Partnering EU Summit 2026
Basel Marriott Hotel, Switzerland
LATEST NEWSRead more...
Apertura Gene Therapy and TSC Alliance Collaborate to Advance Gene Therapy for Tuberous Sclerosis Complex
Apertura Gene Therapy a biotechnology company focused on nextgeneration AAV capsids for gene delivery has entered into a collaboration with the TSC Alliance a nonprofit organisation dedicated to improving
Cellenkos Secures FDA Clearance to Begin CK0802 Trial in Steroid-Refractory GVHD
Cellenkos a clinicalstage biotechnology company focused on developing allogeneic tissuetargeted regulatory T cell Treg therapies has received clearance from the US Food and Drug Administration to proceed
UCB's $2B Candid Acquisition Targets Autoimmune Expansion
UCB inks a landmark billion deal to acquire Candid Therapeutics positioning itself alongside Gilead in the rapidly expanding autoimmune disease treatment market
FDA Clears Pfizer-Arvinas PROTAC for Breast Cancer
The FDA has granted approval to Pfizer and Arvinas groundbreaking oral PROTAC degrader marking a significant advancement in targeted therapies for a specific breast cancer subtype
FDA Greenlights Advanced Biopharma Manufacturing Tech
The US FDA has approved a cuttingedge biopharma manufacturing platform that promises to streamline production processes and reduce costs for American drug manufacturers
Expression Therapeutics Secures FDA Fast Track and Rare Paediatric Disease Designations for Haemophilia A Therapy
Expression Therapeutics has received Fast Track and Rare Paediatric Disease designations from the US Food and Drug Administration for its investigational autologous stem cell therapy for haemophilia A
